PURASORB PDLG 5002 is a 50:50 poly(DL-lactide-co-glycolide) copolymer with acid-terminated chain ends and an inherent viscosity specification of 0.16–0.24 dL/g measured in chloroform at 25 °C and 0.1 g/dL. In downstream drug delivery conversion, the acid termination shortens the induction period for bulk hydrolysis relative to ester-capped PLGA grades of equivalent molar mass, which becomes operationally significant in hot-melt extrusion, solvent removal, and terminal sterilization. The information below is organized by actual manufacturing route rather than therapeutic class.

Why Does Acid Termination in PDLG 5002 Narrow the Residual Solvent Window for Long-Acting Injectable Microspheres?

The O/W solvent extraction/evaporation route for long-acting injectable microspheres uses PURASORB PDLG 5002 dissolved in dichloromethane at 15–25 % w/v, with drug loadings typically between 10 and 40 wt% of total solids for hydrophobic peptide salts and small molecules. The aqueous continuous phase contains polyvinyl alcohol at 0.5–2.0 % w/v, buffered to pH 5.0–7.4 with phosphate or citrate. Emulsification on a Silverson L5M-A high-shear mixer at 3,500–7,000 rpm for 2–5 min produces a pre-hardened droplet population of 15–80 µm. Acid-terminated chain ends accelerate the onset of bulk erosion once the polymer matrix hydrates, but the same hydrophilicity raises the equilibrium moisture content of the polymer before processing; therefore the lyophilized polymer must be equilibrated in vacuum at 25–30 °C for at least 24 h when ambient RH exceeds 60 % prior to weighing and dissolution.

Residual solvent control is the critical compliance boundary. ICH Q3C class 2 limits require dichloromethane below 600 ppm and chloroform below 60 ppm in the finished microsphere powder, measured by headspace GC according to USP <467>. Parenteral particulate matter limits are defined by USP <788>, and sterility is evaluated by USP <71>. Endotoxin content is controlled to <0.5 EU/mg using Limulus amebocyte lysate kinetics per USP <85>. In vitro release is characterized with Apparatus IV flow-through cells, typically 50 mM phosphate-buffered saline pH 7.4 with 0.02 % w/v sodium azide at 37 °C; biologically relevant media containing 0.5 % sodium dodecyl sulfate may be required for poorly soluble payloads. Solvent extraction is performed in a 1–5 L jacketed baffled vessel with overhead stirring at 300–600 rpm for 2–4 h, followed by vacuum filtration on 10 µm stainless steel mesh and lyophilization.

Finished dosage forms include vials of lyophilized microsphere powder reconstituted immediately before deep intramuscular injection with an aqueous vehicle containing sodium carboxymethylcellulose and mannitol, as well as dual-chamber syringes that separate dry powder from diluent. The syringe configuration demands that the microsphere suspension passes through a 19G–21G needle without clogging, which is verified by a maximum injection force below 25 N on a texture analyzer at 1 mL/min extension. Marketed long-acting injection classes in this route include leuprolide acetate, octreotide acetate, exenatide, risperidone, and naltrexone, although the specific release profile must be re-established for each drug because the acid-terminated matrix can shift the lag phase.

When N-Methyl-2-pyrrolidone Replaces Halogenated Solvents in Subcutaneous Phase-Inversion Depots

Phase-inversion depots eliminate microsphere drying and terminal powder handling by co-dissolving PURASORB PDLG 5002 and the active pharmaceutical ingredient in N-methyl-2-pyrrolidone at polymer concentrations of 30–50 wt% and drug loadings of 5–20 wt% relative to total syringe contents. The resulting solution viscosity is characterized on a Brookfield DV3T rheometer with CP-52 spindle at 25 °C; acceptable injection forces through a 21G needle remain below 30 N at 1 mL/min displacement, which typically corresponds to solution viscosity between 500 and 3,000 mPa·s. Once injected into subcutaneous tissue, the water-miscible NMP leaves the depot and water influx precipitates the PLGA matrix, trapping the drug in a solidifying implant. The acid-terminated surface of PDLG 5002 increases the initial water uptake rate relative to ester-capped 50:50 PLGA of the same inherent viscosity, which shortens lag phase but also requires tighter control of initial burst.

Compliance hinges on solvent toxicology and subvisible particulate. NMP is an ICH Q3C class 2 solvent with a permitted daily exposure of 5.3 mg/day and a concentration limit of 530 ppm in the finished product. The prefilled syringe is terminally sterilized by gamma irradiation at 25–40 kGy according to ISO 11137; however irradiation of PLGA at room temperature reduces molecular weight and can raise the 24 h burst release by 10–30 % unless the syringe contents are frozen or the dose is mapped to the low end of the validated range. Sterile filtration is generally not feasible because of viscosity; therefore aseptic processing with terminal sterilization is preferred. Biocompatibility endpoints follow ISO 10993-4 for blood contact, ISO 10993-5 for cytotoxicity, and ISO 10993-6 for local implantation.

Manufacturing uses a jacketed glass or stainless steel vessel under vacuum and dry nitrogen, with dissolution at 40–60 °C under 50–100 rpm anchor stirring until a clear solution is achieved, followed by degassing at −0.8 bar for 12–24 h. Filling into prefilled syringes occurs under controlled relative humidity below 30 % and at 15–25 °C. Terminal products are single-dose prefilled syringes or vials with transfer needle systems for subcutaneous administration of leuprolide acetate and other peptide analogues; the syringe barrel is typically cyclic olefin polymer with fluoropolymer-coated plunger to reduce gliding force.

Hot-melt extrusion of PURASORB PDLG 5002 into a subcutaneous implant rod for 8–12-week release uses a co-rotating twin-screw extruder with a screw diameter of 11–16 mm and an L/D ratio of 25:1–40:1, configured with conveying elements, one kneading block, and a vacuum vent. The formulation is a dry blend of PLGA at 65–85 wt%, drug at 10–30 wt%, and optionally 5–10 wt% plasticizer such as triethyl citrate or acetyl tributyl citrate; the blend is fed at 200–500 g/h under nitrogen. Barrel zone temperatures are set from 70 °C at the feed throat to 95–110 °C at the die, with screw speed 50–150 rpm and melt pressure 10–40 bar. Acid-terminated PLGA hydrolyzes faster than ester-capped PLGA during prolonged melt residency, so the residence time distribution must be held within 1–3 min by balancing feed rate and screw speed; process failures typically appear as yellowing at the die, a reduction of inherent viscosity below 0.15 dL/g, and a rise in release burst above 25 % at 24 h.

Compliance for the extruded rod includes ISO 11607-1:2019 for sterile barrier packaging, ISO 11137 for gamma terminal sterilization, USP <905> for content uniformity of the single-rod dose, and USP <790> for visible particulates in the applicator. Residual monomers lactide and glycolide are monitored by HPLC or GC after alkaline hydrolysis; the sum of residual monomers is controlled below 0.5 % w/w in the finished implant, with water content below 0.3 % w/w by Karl Fischer titration. In vitro release testing uses USP Apparatus IV with 50 mM PBS pH 7.4 at 37 °C, and the terminal product is a sterile single-rod implant preloaded in a 14G or 16G trocar applicator for subcutaneous insertion.

Pulmonary Microparticle Drying Kinetics, Cascade Impaction, and Capsule Fill Control

Spray-dried PLGA microparticles for dry powder inhalation are formulated with PURASORB PDLG 5002 as the matrix at 70–90 wt%, active drug at 5–20 wt%, and L-leucine or trileucine at 5–20 wt% as a shell-dispersing excipient. The feed solution is prepared in dichloromethane or a dichloromethane/ethanol mixture at total solids 0.5–2.0 % w/v. Drying is performed on a Büchi B-290 laboratory spray dryer or an Anhydro pilot unit with a two-fluid nozzle orifice of 0.7 mm, inlet temperature 60–85 °C, outlet temperature 35–50 °C, atomizing air 400–800 L/h, and liquid feed 1–10 mL/min. The terminal aerodynamic size target is 1–5 µm mass median aerodynamic diameter, measured on a Next Generation Impactor at 60 L/min according to USP <601> and Ph. Eur. 2.9.18; fine particle fractions above 30 % are generally required for pulmonary deposition, with emitted dose uniformity within ±15 % across capsule actuations.

Residual solvent limits follow USP <467> and ICH Q3C, specifically 600 ppm for dichloromethane and 5000 ppm for ethanol as a class 3 solvent. After spray drying, the powder is filled into hydroxypropyl methylcellulose capsules at 15–25 °C and <30 % RH, with fill weight 5–25 mg per capsule. The terminal finished forms include capsule-based dry powder inhalers and blister strips; capsule puncture and dispersion are verified by shot weight and aerodynamic particle size distribution across capsule life. Published data for this specific configuration are limited for very hygroscopic payloads, and the 50:50 acid-terminated matrix may require additional leucine to prevent powder adhesion in the capsule.

An intravitreal sustained-release rod produced from PURASORB PDLG 5002 requires a diameter that does not exceed 0.46 mm and a length between 3 and 8 mm to pass through a 22G applicator needle without excessive scleral trauma. The formulation contains PLGA at 40–70 wt% and corticosteroid or anti-VEGF small molecule at 30–60 wt%, with no liquid excipient because solvent residues in the vitreous are poorly tolerated; drug-polymer blends are either hot-melt extruded at 70–100 °C or compression-molded at 60–80 °C under 5–15 kN force. The rod is cut from extrudate under a laminar flow isolator, loaded into a custom applicator, and sealed in a foil pouch under nitrogen. Terminal sterilization is by gamma irradiation at 25 kGy; because PLGA molecular weight falls by 10–30 % at this dose, the initial inherent viscosity must be selected at the high end of the specification.

Compliance for intraocular use is anchored to ISO 10993-5 for cytotoxicity, ISO 10993-6 for intraocular implantation, USP <789> for ophthalmic particulate matter, and ICH Q3C residual solvent limits of 600 ppm dichloromethane if solvent casting was used. In vitro release testing uses USP Apparatus VII with 50 mM PBS or simulated vitreous fluid at 37 °C, with the terminal product being a preloaded 22G applicator containing a single rod; the device is designed to prevent residual rod retention after actuation.

Drug-Eluting Bioresorbable Coating Validation on Titanium Trauma Fixation Surfaces

PURASORB PDLG 5002 can be applied as a low-molar-mass drug-eluting coating to titanium bone screws or plates where local antibiotic delivery is required during the early fracture healing window. The coating solution consists of PLGA at 5–20 % w/v in ethyl acetate or acetone, with the antimicrobial payload at 10–25 wt% relative to PLGA. Application is by ultrasonic spray coating using a Sono-Tek ExactaCoat system at 1–5 W, 10–25 mm nozzle-substrate distance, and 0.1–0.5 mL/min flow, followed by vacuum curing at 40–55 °C for 24–48 h. The coating thickness is held between 1 and 10 µm as measured by scanning electron microscopy; thickness above 15 µm increases the risk of delamination during screw insertion torque of 2–5 N·m.

Biocompatibility is evaluated according to ISO 10993-4 for hemocompatibility if blood contact is expected, ISO 10993-5 for cytotoxicity, ISO 10993-6 for bone implantation, and ISO 10993-10 for sensitization. Residual solvent is controlled to USP <467> limits; ethyl acetate and acetone are ICH Q3C class 3 solvents with a limit of 5000 ppm. Drug release from the coated surface is measured in USP Apparatus IV with 0.02 % w/v sodium azide in PBS pH 7.4 at 37 °C. Terminal products are sterile blister-packaged implant components with the coating applied prior to final packaging; terminal sterilization by ethylene oxide according to ISO 11135 may be preferred over gamma irradiation because gamma exposure further reduces PLGA molecular weight and accelerates coating detachment.